137 related articles for article (PubMed ID: 11824485)
1. A prospective study of factors influencing adherence to a continuous neuroleptic treatment program in schizophrenia patients during 2 years.
Linden M; Godemann F; Gaebel W; Köpke W; Müller P; Müller-Spahn F; Pietzcker A; Tegeler J
Schizophr Bull; 2001; 27(4):585-96. PubMed ID: 11824485
[TBL] [Abstract][Full Text] [Related]
2. [Patient modified medication: how do schizophrenic patients manage their neuroleptics?].
Hornung WP; Buchkremer G; Redbrake M; Klingberg S
Nervenarzt; 1993 Jul; 64(7):434-9. PubMed ID: 8103569
[TBL] [Abstract][Full Text] [Related]
3. Subjective response to neuroleptics in schizophrenia.
Awad AG
Schizophr Bull; 1993; 19(3):609-18. PubMed ID: 7901897
[TBL] [Abstract][Full Text] [Related]
4. Phase-IV multicentre clinical study of risperidone in the treatment of outpatients with schizophrenia. The RIS-CAN-3 Study Group.
Chouinard G; Kopala L; Labelle A; Beauclair L; Johnson SV; Singh KI
Can J Psychiatry; 1998 Dec; 43(10):1018-25. PubMed ID: 9868567
[TBL] [Abstract][Full Text] [Related]
5. [Acute dyskinesia as the cause of jaw dislocation].
Kozian R; Kiszka T; Peter K; Kühne GE
Psychiatr Prax; 1992 Jul; 19(4):119-21. PubMed ID: 1354880
[TBL] [Abstract][Full Text] [Related]
6. Effects of neuroleptic reduction in schizophrenic outpatients receiving high doses.
Leblanc G; Cormier H; Gagné MA; Vaillancourt S
Can J Psychiatry; 1994 May; 39(4):223-9. PubMed ID: 7913872
[TBL] [Abstract][Full Text] [Related]
7. Clinical predictors of relapse following neuroleptic withdrawal.
Buchanan RW; Kirkpatrick B; Summerfelt A; Hanlon TE; Levine J; Carpenter WT
Biol Psychiatry; 1992 Jul; 32(1):72-8. PubMed ID: 1356490
[TBL] [Abstract][Full Text] [Related]
8. Association of negative symptoms with tardive dyskinesia in schizophrenic patients.
Chiu H; Lau J; Lam L; Shum P
Aust N Z J Psychiatry; 1993 Jun; 27(2):228-32. PubMed ID: 8103320
[TBL] [Abstract][Full Text] [Related]
9. Pharmacological long-term treatment strategies in first episode schizophrenia--study design and preliminary results of an ongoing RCT within the German Research Network on Schizophrenia.
Gaebel W; Möller HJ; Buchkremer G; Ohmann C; Riesbeck M; Wölwer W; Von Wilmsdorff M; Bottlender R; Klingberg S
Eur Arch Psychiatry Clin Neurosci; 2004 Apr; 254(2):129-40. PubMed ID: 15146342
[TBL] [Abstract][Full Text] [Related]
10. Schizophrenic patients' experiences of neuroleptic medication: a Q-methodological investigation.
Day JC; Bentall RP; Warner S
Acta Psychiatr Scand; 1996 May; 93(5):397-402. PubMed ID: 8792911
[TBL] [Abstract][Full Text] [Related]
11. Treatment adherence and insight in schizophrenia.
Bitter I; Fehér L; Tényi T; Czobor P
Psychiatr Hung; 2015; 30(1):18-26. PubMed ID: 25867885
[TBL] [Abstract][Full Text] [Related]
12. [Exacerbation of catatonic symptoms in neuroleptic therapy].
Bräunig P; Krüger S; Höffler J
Nervenarzt; 1995 May; 66(5):379-82. PubMed ID: 7609820
[TBL] [Abstract][Full Text] [Related]
13. Treatment of late-life schizophrenia with neuroleptics.
Jeste DV; Lacro JP; Gilbert PL; Kline J; Kline N
Schizophr Bull; 1993; 19(4):817-30. PubMed ID: 7905663
[TBL] [Abstract][Full Text] [Related]
14. Neuroleptic dosing in chronic schizophrenia: a 10-year follow-up.
Remington GJ; Prendergast P; Bezchlibnyk-Butler KZ
Can J Psychiatry; 1997 Feb; 42(1):53-7. PubMed ID: 9040924
[TBL] [Abstract][Full Text] [Related]
15. Improvement of patient compliance after switching from conventional neuroleptics to the atypical neuroleptic amisulpride.
Linden M; Scheel T; Eich FX
J Psychopharmacol; 2006 Nov; 20(6):815-23. PubMed ID: 16401647
[TBL] [Abstract][Full Text] [Related]
16. Predicting neuroleptic response from a combination of multilevel variables in acute schizophrenic patients.
Bartkó G; Frecska E; Horváth S; Zádor G; Arató M
Acta Psychiatr Scand; 1990 Dec; 82(6):408-12. PubMed ID: 1981296
[TBL] [Abstract][Full Text] [Related]
17. [Comparison of 2 depression scales and their relationship with negative and akinetic symptoms in stabilized schizophrenic patients].
Langlois-Thery S; Dollfus S; Lesieur P; Petit M
Encephale; 1994; 20(5):487-93. PubMed ID: 7828511
[TBL] [Abstract][Full Text] [Related]
18. Study of the clinical utility of radioreceptor assay in outpatients with schizophrenia receiving high doses of neuroleptics.
Gagné MA; Cormier H; Leblanc G; Lévesque D; Di Paolo T
Can J Psychiatry; 1993 Oct; 38(8):534-40. PubMed ID: 7902199
[TBL] [Abstract][Full Text] [Related]
19. Neuroleptic-induced emesis: a new indication for clozapine?
Bustillo JR; Buchanan RW
Biol Psychiatry; 1995 Aug; 38(3):194-5. PubMed ID: 7578665
[No Abstract] [Full Text] [Related]
20. Movement disorder in never and minimally treated Nigerian schizophrenic patients.
McCreadie RG; Ohaeri JU
Br J Psychiatry; 1994 Feb; 164(2):184-9. PubMed ID: 7909712
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
